1305267-37-1
1305267-37-1 structure
- Name: MSC2360844
- Chemical Name: MSC2360844
- CAS Number: 1305267-37-1
- Molecular Formula: C26H27FN4O5S
- Molecular Weight: 526.58
- Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
- Create Date: 2020-04-13 21:47:04
- Modify Date: 2024-09-18 11:00:17
-
MSC2360844 is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases[1].
| Name | MSC2360844 |
|---|
| Description | MSC2360844 is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases[1]. |
|---|---|
| Related Catalog | |
| Target |
PI3Kδ:145 nM (IC50) |
| In Vitro | MSC2360844 (0-10 μM; 1 hours) completely abolished BCR-induced pAkt in Ramos B cells in a concentration-dependent manner with IC50 values of 280 nM[1]. MSC2360844 inhibits B cell proliferation in a concentration-dependent manner with an IC50 of 48 nM. MSC2360844 blocks BCR- and TCR-mediated responses in lymphocytes and TLR-induced IFNα by pDC in human primary cells[1]. Cell Proliferation Assay[1] Cell Line: B cells Concentration: 0-10 μM Incubation Time: 1 hour Result: Inhibited B cell proliferation in a concentration-dependent manner with an IC50 of 48 nM. |
| In Vivo | MSC2360844 (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model[1]. Animal Model: NZB/W F1 female mice[1] Dosage: 6.6, 22, or 66 mg/kg Administration: Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10 weeks Result: Significantly reduced proteinuria incidence and severity in a dose-dependent manner. |
| References |
| Molecular Formula | C26H27FN4O5S |
|---|---|
| Molecular Weight | 526.58 |